# Novamab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novamab

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.novamab.com
- Total disclosed funding: $101M
- Latest round: Series B (Apr 23, 2026)
- Investors on record: 15

## About

Based in Shanghai, China and founded in 2017, Shanghai Novamab Biopharmaceuticals Co., Ltd., trading as Novamab, , is a pharmaceutical company that focuses on the research and development of nano-antibody drugs. It has an R&D and production base of more than 7,500 square meters, as well as a camel breeding base, with nearly 90 employees.  Yakun Wan, the founder, chairman, and CEO of the company, is the director of the Nano Antibody Engineering Technology R&D Center in Jiangsu Province. The company acquired 24 patents. In 2023, its inhaled TSLP nano-antibody drug LQ043H was approved for clinical trials in China. In April 2026, Novamab raised approximately CNY 300 million in Series B+ funding led by Qiming Venture Partners, with participation from Jiuyu Investment, Fuho Capital, Nanwan Baiao Fund, Jinyuan Kuntong Equity Investment Management, Zhaode Investment, Sunland and Guangdong Technology Financial Group.
The company's business is inhaled nano-antibody drug research and development. It has technology platforms based on nano-antibodies, including a nanoantibody screening platform, a picrosystem CMC process development platform, and an inhalation macromolecule drug discovery and development platform. The company has pipelines in respiratory diseases, immune diseases, and tumors, such as LQ036, LQ043, LQ056, and LQ059.
The company’s revenue is generated by providing innovative nano-antibody drugs.
The Series B+ funding raised in April 2026 will be primarily used in three areas: first, to advance the Phase IIb clinical trial of the Company's core inhaled nanobody pipeline, LQ036, which is currently progressing smoothly in patient enrollment; second, to focus on the development and implementation of the oral nanobody platform and related pipelines, improving the technology platform layout; and third, to strengthen team building, supplementing core R&D and operational talent to support the Company's sustainable development.

## Funding rounds

- Series B, Apr 23, 2026, $44M — Qiming Venture Partners, Guangdong Technology Financial Group, Fuho Capital, Jinyuan Kuntong Equity Investment Management, Jiuyu Investment, Nanwan Baiao Fund, Sunland, Zhaode Investment
- Series B, Jul 31, 2024, $28M — Qiming Venture Partners, Jiuyu Investment, Shengdi Investment, Huangpu Biomedical Investment
- Series B, Dec 20, 2023, $14M — BIO-TOWN Capital, Shengdi Investment
- Series A, Apr 8, 2021 — Tao Capital, Jiangsu Zijin Hongyun Health Industry Investment Partnership
- Series A, Mar 12, 2021, $15M — Fuho Capital, TigerYeah Capital, Tianhui Fund

## Investors

- Fuho Capital (https://capitalatlas.ai/funds/fuho-capital) — Series A, Series B
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Tianhui Fund — Series A
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A
- Jiangsu Zijin Hongyun Health Industry Investment Partnership — Series A
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series B
- Shengdi Investment — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Jiuyu Investment (https://capitalatlas.ai/funds/jiuyu-investment) — Series B
- Huangpu Biomedical Investment (https://capitalatlas.ai/funds/huangpu-biomedical-investment) — Series B
- Guangdong Technology Financial Group (https://capitalatlas.ai/funds/guangdong-technology-financial-group) — Series B
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series B
- Nanwan Baiao Fund — Series B
- Sunland — Series B
- Zhaode Investment — Series B